CD33 Monoclonal Antibody (P67.6), APC, eBioscience™, Invitrogen™

Description

• Description: The P67.6 monoclonal antibody reacts with human CD33 (also known as GP67 and P67), a 67 kDa type I transmembrane glycoprotein that is a member of the Siglec (sialic acid-binding Ig superfamily lectin) family
• It is highly specific to the hematopoietic compartment and is expressed on monocytes, activated T cells, granulocytes, myeloid progenitors, and mast cells
• Applications Reported: This P67.6 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This P67.6 antibody has been pre-diluted and tested by flow cytometric analysis of normal human peripheral blood cells
• This may be used at 5 μL (0.06 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family
• It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies, and these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface
• CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia
• Further, CD33 is found on granulocyte and macrophage precursors in the bone marrow, but is not on pluripotent stem cells
• CD33 is also expressed on, and is a useful marker for, peripheral monocytes
• CD33 is useful for distinguishing myelogenous leukemia cells from lymphoid or erythroid leukemias
• Diseases associated with CD43 dysfunction include gallbladder lymphoma and extracutaneous mastocytoma.